Showing results (1-10 of 19) with videos related to
Sort By:
Pageof 2
Clinical Therapeutics|January 1, 1990
Ocular bioavailability of topical prednisolone preparationsO Olejnik, C A WeisbeckerDrug Intelligence & Clinical Pharmacy|September 1, 1985
Antimicrobial drug delivery to the eyeT S Lesar, R G FiscellaJournal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|January 1, 1996
Biotransformation in review: applications in ocular disease and drug designB I Gaynes, R G FiscellaInvestigative Ophthalmology & Visual Science|March 1, 1996
Intraocular penetration of periocular ketorolac and efficacy in experimental uveitisP K Rabiah, R G Fiscella, H H TesslerJournal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|January 1, 1996
Stability of cyclosporine 1% in artificial tearsR G Fiscella, H Le, T T Lam, et al.Retina (Philadelphia, Pa.)|January 1, 1997
Efficacy of dorzolamide hydrochloride in the management of chronic cystoid macular edema in patients with retinitis pigmentosaS Grover, G A Fishman, R G Fiscella, et al.American Journal of Ophthalmology|March 8, 2000
Tissue plasminogen activator to treat impending pupillary block glaucoma in patients with acute fibrinous HLA-B27 positive iridocyclitisC A Skolnick, R G Fiscella, H H Tessler, et al.American Journal of Ophthalmology|November 30, 1999
Cost considerations of medical therapy for glaucomaR G Fiscella, J L Geller, L L Gryz, et al.Indian Journal of Ophthalmology|September 1, 1994
Effect of U74006F (Tirilazad Mesylate) in rabbit eyes after argon laser trabeculoplastyR G Fiscella, S G Asrani, D S Hillman, et al.Ophthalmology|March 1, 1993
Intraocular tissue plasminogen activator concentrations after subconjunctival deliveryJ I Lim, A M Maguire, G John, et al.Pageof 2